FY2025 EPS Estimates for Oncobiologics Increased by Analyst

Oncobiologics, Inc. (NASDAQ:OTLK) – Equities researchers at HC Wainwright upped their FY2025 earnings per share estimates for Oncobiologics in a report released on Monday, August 18th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of ($1.96) per share for the year, up from their previous estimate of ($2.33). The consensus estimate for Oncobiologics’ current full-year earnings is ($2.27) per share. HC Wainwright also issued estimates for Oncobiologics’ Q4 2025 earnings at ($0.23) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.11) EPS, FY2028 earnings at $0.28 EPS and FY2029 earnings at $0.53 EPS.

Oncobiologics (NASDAQ:OTLK) last released its earnings results on Thursday, August 14th. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.02). The business had revenue of $1.51 million during the quarter, compared to analysts’ expectations of $1.66 million.

A number of other research firms also recently weighed in on OTLK. Chardan Capital restated a “neutral” rating and issued a $3.00 target price on shares of Oncobiologics in a research report on Friday, August 15th. Guggenheim restated a “buy” rating on shares of Oncobiologics in a research report on Tuesday, May 20th. Finally, Ascendiant Capital Markets cut their target price on Oncobiologics from $24.00 to $21.00 and set a “buy” rating for the company in a research report on Friday, June 6th. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $9.60.

Oncobiologics Price Performance

OTLK opened at $2.39 on Wednesday. The company has a market capitalization of $80.23 million, a price-to-earnings ratio of -4.19 and a beta of 0.26. Oncobiologics has a 1-year low of $0.87 and a 1-year high of $8.32. The business has a 50 day moving average price of $1.98 and a two-hundred day moving average price of $1.70.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of OTLK. Russell Investments Group Ltd. increased its holdings in shares of Oncobiologics by 34,936.7% in the fourth quarter. Russell Investments Group Ltd. now owns 17,168 shares of the company’s stock valued at $32,000 after buying an additional 17,119 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Oncobiologics during the 4th quarter valued at $246,000. Jane Street Group LLC raised its stake in Oncobiologics by 133.9% during the 4th quarter. Jane Street Group LLC now owns 26,218 shares of the company’s stock valued at $50,000 after purchasing an additional 15,008 shares during the period. AQR Capital Management LLC raised its stake in Oncobiologics by 42.7% during the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after purchasing an additional 25,351 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in Oncobiologics by 74.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock valued at $126,000 after purchasing an additional 44,063 shares during the period. Institutional investors own 11.20% of the company’s stock.

About Oncobiologics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.